Quetmolimab: A Deep Dive into KANAb 001 and E-6011 Quetmo agent, KANAb 001, represents a novel immunotherapy aimed at PD-1. Early study Recombinant Quetmolimab results from the two initiatives, KANAb 001 and E-6011